The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Potassium Acetate
Potassium Acetate · POTASSIUM ACETATE 3.93 g/20mL · Injection, Solution, Concentrate · Intravenous · Fresenius Kabi USA, LLC
NDC 65219-0510-20 · 25 VIAL, SINGLE-DOSE in 1 TRAY / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Part D plans paid (avg)$0.2932per dosage unitgross, before rebates — matched by drug name · 2024
- Federal contracts pay (FSS)$128.42per package of 25X20MLFresenius Kabi, LLC · May 15, 2025
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$134.75
Reported to Texas DSHS · 2026 annual filing · Fresenius Kabi USA
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicaid spend (2025)
$86,927
114 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Fresenius Kabi USA, LLCUnited Statesanalysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $52.05 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Xywav and Xyrem
Regulatory
- Application
- ANDA217515
- TE code
- AP
- Approval date
- Nov 27, 2024
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Potassium Acetate (Injection, Solution, Concentrate)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Hospira, Inc. | POTASSIUM ACETATE 196.3 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Hospira, Inc. | POTASSIUM ACETATE 3.93 g/20mL | Jul 15, 2026 | Sep 3, 2026 |
| Fresenius Kabi USA, LLC | POTASSIUM ACETATE 196 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | POTASSIUM ACETATE 3.93 g/20mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Potassium Acetate — NDC 65219-0510-20," retrieved September 3, 2026, https://drugdashboards.com/drug/65219051020.
Free to cite with attribution — see how the data is put together.